| 54.41 1.76 (3.34%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 66.46 | 1-year : | 77.63 |
| Resists | First : | 56.9 | Second : | 66.46 |
| Pivot price | 49.99 |
|||
| Supports | First : | 48.38 | Second : | 43.12 |
| MAs | MA(5) : | 52.61 |
MA(20) : | 48.72 |
| MA(100) : | 55.74  |
MA(250) : | 56.39 |
|
| MACD | MACD : | 0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 90.5 |
D(3) : | 91.1 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 71.92 | Low : | 43.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TECH ] has closed below upper band by 6.1%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 55.23 - 55.43 | 55.43 - 55.6 |
| Low: | 52.62 - 52.88 | 52.88 - 53.08 |
| Close: | 54.02 - 54.42 | 54.42 - 54.74 |
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
Tue, 09 Jun 2026
Bio-Techne (TECH) Q4 2025 Earnings Transcript - AOL.com
Mon, 08 Jun 2026
Bio-Techne Corp (TECH) Stock Analysis: Exploring a Potential 18% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Sat, 06 Jun 2026
Bio-Techne Corporation Trade Ideas — XETR:TE1 - TradingView
Thu, 04 Jun 2026
Assessing Bio-Techne (TECH) Valuation After Recent Share Price Rebound And Mixed Longer Term Returns - simplywall.st
Thu, 04 Jun 2026
New 4-hour test links charge and size in bispecific antibodies and biosimilars - Stock Titan
Thu, 04 Jun 2026
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 157 (M) |
| Shares Float | 155 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 117.8 (%) |
| Shares Short | 14,550 (K) |
| Shares Short P.Month | 14,000 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.89 |
| Profit Margin | 9 % |
| Operating Margin | 25.1 % |
| Return on Assets (ttm) | 7.4 % |
| Return on Equity (ttm) | 5.3 % |
| Qtrly Rev. Growth | -1.5 % |
| Gross Profit (p.s.) | 5.13 |
| Sales Per Share | 7.72 |
| EBITDA (p.s.) | 2.33 |
| Qtrly Earnings Growth | 128.6 % |
| Operating Cash Flow | 295 (M) |
| Levered Free Cash Flow | 300 (M) |
| PE Ratio | 77.72 |
| PEG Ratio | 0.6 |
| Price to Book value | 4.21 |
| Price to Sales | 7.04 |
| Price to Cash Flow | 28.89 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|